DESCRIPTION

• Format: Lentiviral plasmids
• Refseq: NM_001135648, NM_001291981, NM_001291982, NM_001291983, NM_001291984, NM_002844, NM_002844.1, NM_002844.2, NM_002844.3, NM_001135648.1, NM_001135648.2, NM_001291983.1, NM_001291982.1, NM_001291984.1, NM_001291981.1, BC140775, BC063596, BC144512, BC144513, NM_001291982.2, NM_001291983.2, NM_001291981.2, NM_002844.4, NM_001291984.2, NM_001135648.3
• Status: 2 Weeks*
• Vector: pGFP-C-shLenti
• Summary: The protein encoded by this gene is a member of the protein tyrosine phosphatase (PTP) family. PTPs are known to be signaling molecules that regulate a variety of cellular processes including cell growth, differentiation, mitotic cycle, and oncogenic transformation. This PTP possesses an extracellular region, a single transmembrane region, and two tandem catalytic domains, and thus represents a receptor-type PTP. The extracellular region contains a meprin-A5 antigen-PTP mu (MAM) domain, an Ig-like domain and four fibronectin type III-like repeats. This PTP was shown to mediate homophilic intercellular interaction, possibly through the interaction with beta- and gamma-catenin at adherens junctions. Expression of this gene was found to be stimulated by TGF-beta 1, which may be important for the inhibition of keratinocyte proliferation. [provided by RefSeq, Jul 2008]
• Category: RNAi
• Locus Id: 5796
• Synonyms: R-PTP-kappa
• Uniprot Id: Q15262
• Availability: 2 Weeks
• Shrna Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service.
• Kit Components: PTPRK - Human, 4 unique 29mer shRNA constructs in lentiviral GFP vector(Gene ID = 5796). 5µg purified plasmid DNA per construct29-mer scrambled shRNA cassette in pGFP-C-shLenti Vector, TR30021, included for free.
• E Coli Selection: Chloramphenicol (34 ug/ml)
• Performance Guaranteed: OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples. For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).
• Mammalian Cell Selection: Puromycin